“…This finding has been replicated several times and yet is almost never considered or investigated in clinical AD research where male and female APOE4 carriers are generally viewed as having equal risk(Bretsky et al, 1999; Payami et al, 1996). In the few recent studies that have examined this interaction between APOE4 and gender, female, but not male, APOE4 carriers have shown more pronounced AD-like changes in neuroimaging, neuropathological, and neuropsychological measures when compared to their APOE3 homozygous peers(Corder et al, 2004; Damoiseaux, Seeley, et al, 2012; Fleisher et al, 2005; Lehmann et al, 2006). In mouse models designed for AD research, the same interaction between APOE and gender was identified years ago, so that today many studies only carry out experiments in female mice(Andrews-Zwilling et al, 2010; Raber, Bongers, LeFevour, Buttini, & Mucke, 2002; Raber et al, 1998).…”